Summary
This 2025 guideline from the American College of Cardiology and American Heart Association consolidates updated evidence for managing acute coronary syndromes, superseding prior guidelines from 2013–2016. The document incorporates new clinical studies, systematic reviews, and meta-analyses published through April 2024 to provide contemporary recommendations for diagnosis, risk assessment, and therapeutic intervention. Many previous recommendations have been revised with new evidence, and novel recommendations have been added where supported by published data.
UK applicability
Whilst this guideline reflects United States clinical practice standards and may not be directly transferable, UK clinicians may find value in the synthesised evidence base for comparative review against UK National Institute for Health and Care Excellence (NICE) guidance on acute coronary syndromes and percutaneous coronary intervention protocols. Adoption would require review by UK regulatory and professional bodies.
Key measures
Clinical practice recommendations based on systematic evidence review; updates to previous 2013-2016 ACC/AHA guidelines on acute coronary syndrome management and percutaneous coronary intervention
Outcomes reported
The guideline synthesises evidence on the diagnosis, risk stratification, and management of patients presenting with acute coronary syndromes, including ST-elevation and non-ST-elevation myocardial infarction. It provides updated clinical recommendations incorporating new evidence from systematic literature review conducted between July 2023 and April 2024.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.